Summary
3.83 -0.01(-0.26%)07/05/2024
Outset Medical Inc (OM)
Outset Medical Inc (OM)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.00 | -0.78 | -6.01 | 87.29 | -31.24 | -80.99 | 0.00 | -93.69 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 3.83 | |
| Open | 3.83 | |
| High | 3.91 | |
| Low | 3.71 | |
| Volume | 563,630 | |
| Change | 0.00 | |
| Change % | 0.00 | |
| Avg Volume (20 Days) | 1,063,196 | |
| Volume/Avg Volume (20 Days) Ratio | 0.53 | |
| 52 Week Range | 1.92 - 20.96 | |
| Price vs 52 Week High | -81.73% | |
| Price vs 52 Week Low | 99.48% | |
| Range | 0.00 | |
| Gap Up/Down | -0.06 | |
Fundamentals | ||
| Market Capitalization (Mln) | 198 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 63.80 | |
| Book Value | 8.7150 | |
| Earnings Per Share | -2.7030 | |
| EPS Estimate Current Quarter | -0.7300 | |
| EPS Estimate Next Quarter | -0.7700 | |
| EPS Estimate Current Year | -2.8000 | |
| EPS Estimate Next Year | -2.4900 | |
| Diluted EPS (TTM) | -2.7030 | |
| Revenues | ||
| Profit Marging | -1.3386 | |
| Operating Marging (TTM) | -1.3232 | |
| Return on asset (TTM) | -0.1658 | |
| Return on equity (TTM) | -0.3213 | |
| Revenue TTM | 91,697,000 | |
| Revenue per share TTM | 2.0190 | |
| Quarterly Revenue Growth (YOY) | 0.9130 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -13,037,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 5.2283 | |
| Revenue Enterprise Value | 19.7098 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 47,094,300 | |
| Shares Float | 37,810,613 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.70 | |
| Institutions (%) | 113.47 | |
07/01 06:00 EST - investorplace.com
3 MedTech Stocks to Buy for Healthy Gains
Fundamentally, few sectors exist outside of the broad healthcare umbrella that offer what I would term permanent relevance. In this case, the concept of caring for other people is likely an eternal one.
3 MedTech Stocks to Buy for Healthy Gains
Fundamentally, few sectors exist outside of the broad healthcare umbrella that offer what I would term permanent relevance. In this case, the concept of caring for other people is likely an eternal one.
06/10 13:01 EST - zacks.com
Outset Medical (OM) Upgraded to Buy: What Does It Mean for the Stock?
Outset Medical (OM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Outset Medical (OM) Upgraded to Buy: What Does It Mean for the Stock?
Outset Medical (OM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
06/03 16:05 EST - businesswire.com
Outset Medical to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that management will present at the Goldman Sachs 45th annual Healthcare conference on Wednesday, June 12, 2024, at 11:20 a.m. Eastern time. A live and archived webcast of the presentation will be available on the “Investors” section of the Outset website at https://investors.outsetm.
Outset Medical to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that management will present at the Goldman Sachs 45th annual Healthcare conference on Wednesday, June 12, 2024, at 11:20 a.m. Eastern time. A live and archived webcast of the presentation will be available on the “Investors” section of the Outset website at https://investors.outsetm.
05/20 07:30 EST - https://www.defenseworld.net
Outset Medical, Inc. (NASDAQ:OM) General Counsel Sells $10,491.16 in Stock
Outset Medical, Inc. (NASDAQ:OM – Get Free Report) General Counsel John L. Brottem sold 2,972 shares of the stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $3.53, for a total value of $10,491.16. Following the sale, the general counsel now owns 243,875 shares in the company, valued at $860,878.75. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Outset Medical Stock Performance Shares of OM opened at $3.61 on Monday. The company has a quick ratio of 5.32, a current ratio of 6.42 and a debt-to-equity ratio of 2.11. Outset Medical, Inc. has a one year low of $1.92 and a one year high of $24.13. The business has a fifty day moving average of $2.55 and a 200 day moving average of $3.76. Outset Medical (NASDAQ:OM – Get Free Report) last released its quarterly earnings results on Wednesday, February 21st. The company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.03). The firm had revenue of $30.51 million for the quarter, compared to the consensus estimate of $30.40 million. Outset Medical had a negative net margin of 134.93% and a negative return on equity of 120.67%. As a group, sell-side analysts anticipate that Outset Medical, Inc. will post -2.23 earnings per share for the current fiscal year. Analyst Ratings Changes A number of brokerages have recently issued reports on OM. BTIG Research began coverage on Outset Medical in a report on Monday, April 8th. They set a “buy” rating and a $6.00 price target on the stock. CL King raised shares of Outset Medical from a “neutral” rating to a “buy” rating and set a $6.00 price target on the stock in a report on Friday, April 5th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $5.42. Read Our Latest Analysis on OM Institutional Investors Weigh In On Outset Medical Several hedge funds and other institutional investors have recently modified their holdings of OM. State Board of Administration of Florida Retirement System boosted its position in shares of Outset Medical by 33.4% in the first quarter. State Board of Administration of Florida Retirement System now owns 18,842 shares of the company’s stock worth $42,000 after purchasing an additional 4,720 shares during the period. Nisa Investment Advisors LLC boosted its holdings in Outset Medical by 1,317.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 8,790 shares of the company’s stock worth $48,000 after buying an additional 8,170 shares during the period. RPO LLC bought a new stake in Outset Medical during the fourth quarter valued at about $76,000. Valeo Financial Advisors LLC purchased a new position in shares of Outset Medical in the fourth quarter valued at about $117,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of Outset Medical in the fourth quarter valued at about $161,000. About Outset Medical (Get Free Report) Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. Read More Five stocks we like better than Outset Medical Conference Calls and Individual Investors Canada Goose Flies Higher Driven By DTC Growth What is the S&P/TSX Index? CVS Health Stock Has a Silver Lining Called Value ESG Stocks, What Investors Should Know Magnificent 7 Still Magnificent as the Halfway Mark Approaches?
Outset Medical, Inc. (NASDAQ:OM) General Counsel Sells $10,491.16 in Stock
Outset Medical, Inc. (NASDAQ:OM – Get Free Report) General Counsel John L. Brottem sold 2,972 shares of the stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $3.53, for a total value of $10,491.16. Following the sale, the general counsel now owns 243,875 shares in the company, valued at $860,878.75. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Outset Medical Stock Performance Shares of OM opened at $3.61 on Monday. The company has a quick ratio of 5.32, a current ratio of 6.42 and a debt-to-equity ratio of 2.11. Outset Medical, Inc. has a one year low of $1.92 and a one year high of $24.13. The business has a fifty day moving average of $2.55 and a 200 day moving average of $3.76. Outset Medical (NASDAQ:OM – Get Free Report) last released its quarterly earnings results on Wednesday, February 21st. The company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.03). The firm had revenue of $30.51 million for the quarter, compared to the consensus estimate of $30.40 million. Outset Medical had a negative net margin of 134.93% and a negative return on equity of 120.67%. As a group, sell-side analysts anticipate that Outset Medical, Inc. will post -2.23 earnings per share for the current fiscal year. Analyst Ratings Changes A number of brokerages have recently issued reports on OM. BTIG Research began coverage on Outset Medical in a report on Monday, April 8th. They set a “buy” rating and a $6.00 price target on the stock. CL King raised shares of Outset Medical from a “neutral” rating to a “buy” rating and set a $6.00 price target on the stock in a report on Friday, April 5th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $5.42. Read Our Latest Analysis on OM Institutional Investors Weigh In On Outset Medical Several hedge funds and other institutional investors have recently modified their holdings of OM. State Board of Administration of Florida Retirement System boosted its position in shares of Outset Medical by 33.4% in the first quarter. State Board of Administration of Florida Retirement System now owns 18,842 shares of the company’s stock worth $42,000 after purchasing an additional 4,720 shares during the period. Nisa Investment Advisors LLC boosted its holdings in Outset Medical by 1,317.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 8,790 shares of the company’s stock worth $48,000 after buying an additional 8,170 shares during the period. RPO LLC bought a new stake in Outset Medical during the fourth quarter valued at about $76,000. Valeo Financial Advisors LLC purchased a new position in shares of Outset Medical in the fourth quarter valued at about $117,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of Outset Medical in the fourth quarter valued at about $161,000. About Outset Medical (Get Free Report) Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. Read More Five stocks we like better than Outset Medical Conference Calls and Individual Investors Canada Goose Flies Higher Driven By DTC Growth What is the S&P/TSX Index? CVS Health Stock Has a Silver Lining Called Value ESG Stocks, What Investors Should Know Magnificent 7 Still Magnificent as the Halfway Mark Approaches?
05/08 19:44 EST - seekingalpha.com
Outset Medical, Inc. (OM) Q1 2024 Earnings Call Transcript
Outset Medical, Inc. (NASDAQ:OM ) Q1 2024 Earnings Conference Call May 8, 2024 5:00 PM ET Company Participants Jim Mazzola - Head, IR Leslie Trigg - Chair & CEO Nabeel Ahmed - CFO Conference Call Participants Rick Wise - Stifel Shagun Sing - RBC Capital Markets Marie Thibault - BTIG Kristen Stewart - CL King Suraj Kalia - Oppenheimer Stephanie Piazzola - Bank of America Securities Joshua Jennings - TD Cowen Operator Good day and thank you for standing by. Welcome to the Outset Medical Q1 2024 Earnings Conference Call.
Outset Medical, Inc. (OM) Q1 2024 Earnings Call Transcript
Outset Medical, Inc. (NASDAQ:OM ) Q1 2024 Earnings Conference Call May 8, 2024 5:00 PM ET Company Participants Jim Mazzola - Head, IR Leslie Trigg - Chair & CEO Nabeel Ahmed - CFO Conference Call Participants Rick Wise - Stifel Shagun Sing - RBC Capital Markets Marie Thibault - BTIG Kristen Stewart - CL King Suraj Kalia - Oppenheimer Stephanie Piazzola - Bank of America Securities Joshua Jennings - TD Cowen Operator Good day and thank you for standing by. Welcome to the Outset Medical Q1 2024 Earnings Conference Call.
05/08 18:46 EST - zacks.com
Outset Medical, Inc. (OM) Reports Q1 Loss, Misses Revenue Estimates
Outset Medical, Inc. (OM) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.72 per share a year ago.
Outset Medical, Inc. (OM) Reports Q1 Loss, Misses Revenue Estimates
Outset Medical, Inc. (OM) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.72 per share a year ago.
05/01 16:30 EST - businesswire.com
Outset Medical to Present at Upcoming Investor Conferences
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate at the BofA Securities Health Care conference on Tuesday, May 14, 2024 at 2:20 p.m. Eastern time/11:20 a.m. Pacific time, and at the RBC Capital Markets Global Health Care conference on Wednesday, May 15, 2024 at 1:35 p.m. Eastern time/10:3.
Outset Medical to Present at Upcoming Investor Conferences
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate at the BofA Securities Health Care conference on Tuesday, May 14, 2024 at 2:20 p.m. Eastern time/11:20 a.m. Pacific time, and at the RBC Capital Markets Global Health Care conference on Wednesday, May 15, 2024 at 1:35 p.m. Eastern time/10:3.
04/19 08:30 EST - businesswire.com
Outset Medical to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the first quarter of 2024 after the close of trading on Wednesday, May 8, 2024. On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer,.
Outset Medical to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the first quarter of 2024 after the close of trading on Wednesday, May 8, 2024. On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer,.
04/18 14:41 EST - zacks.com
Outset Medical (OM) Inks Multi-Year Deal to Boost Home Dialysis
Outset Medical's (OM) latest agreement is likely to provide patients and caregivers access to innovative home dialysis with the Tablo Hemodialysis System.
Outset Medical (OM) Inks Multi-Year Deal to Boost Home Dialysis
Outset Medical's (OM) latest agreement is likely to provide patients and caregivers access to innovative home dialysis with the Tablo Hemodialysis System.
04/17 08:30 EST - businesswire.com
Outset Medical and U.S. Renal Care Announce Multi-Year Agreement to Accelerate and Grow Home Dialysis Across the U.S.
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, and U.S. Renal Care, the largest privately held kidney care provider in the United States, announced today a multi-year agreement to help accelerate home hemodialysis in the U.S. Studies show patients with end-stage kidney disease (ESKD) are healthier mentally and physically dialyzing at home, more.
Outset Medical and U.S. Renal Care Announce Multi-Year Agreement to Accelerate and Grow Home Dialysis Across the U.S.
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, and U.S. Renal Care, the largest privately held kidney care provider in the United States, announced today a multi-year agreement to help accelerate home hemodialysis in the U.S. Studies show patients with end-stage kidney disease (ESKD) are healthier mentally and physically dialyzing at home, more.
04/15 08:30 EST - businesswire.com
Outset Medical Partners with American Nephrology Nurses Association to Support Nephrology Nursing and Patient Care
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced its partnership with the American Nephrology Nurses Association (ANNA) as a member of its new Partnership Advisory Council. This collaboration underscores Outset's dedication to supporting the nephrology nursing community and improving patient care in the realm of kidney disease. Les.
Outset Medical Partners with American Nephrology Nurses Association to Support Nephrology Nursing and Patient Care
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced its partnership with the American Nephrology Nurses Association (ANNA) as a member of its new Partnership Advisory Council. This collaboration underscores Outset's dedication to supporting the nephrology nursing community and improving patient care in the realm of kidney disease. Les.
03/19 08:08 EST - benzinga.com
Top 5 Health Care Stocks Which Could Rescue Your Portfolio In March - Inspire Veterinary (NASDAQ:IVP), Fractyl Health (NASDAQ:GUTS)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Top 5 Health Care Stocks Which Could Rescue Your Portfolio In March - Inspire Veterinary (NASDAQ:IVP), Fractyl Health (NASDAQ:GUTS)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
03/13 16:02 EST - businesswire.com
Outset Medical Announces Appointment of Medical Technology Veteran Brent D. Lang to its Board of Directors
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of medical technology veteran Brent D. Lang to its board of directors. Mr. Lang most recently served as Chairman and Chief Executive Officer of Vocera Communications, a global provider of clinical communication and workflow solutions, until its acquisition by Stryker.
Outset Medical Announces Appointment of Medical Technology Veteran Brent D. Lang to its Board of Directors
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of medical technology veteran Brent D. Lang to its board of directors. Mr. Lang most recently served as Chairman and Chief Executive Officer of Vocera Communications, a global provider of clinical communication and workflow solutions, until its acquisition by Stryker.
02/26 09:00 EST - businesswire.com
Outset Medical to Present at the 44th Annual TD Cowen Health Care Conference
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will present at the 44th annual TD Cowen Health Care conference on Tuesday, March 5, 2024, at 1:30 p.m. Eastern time. A live and archived webcast of the presentation will be available on the “Investors” section of the Outset website at https://investors.out.
Outset Medical to Present at the 44th Annual TD Cowen Health Care Conference
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will present at the 44th annual TD Cowen Health Care conference on Tuesday, March 5, 2024, at 1:30 p.m. Eastern time. A live and archived webcast of the presentation will be available on the “Investors” section of the Outset website at https://investors.out.
02/21 23:59 EST - seekingalpha.com
Outset Medical, Inc. (OM) Q4 2023 Earnings Call Transcript
Outset Medical, Inc. (OM) Q4 2023 Earnings Call Transcript
Outset Medical, Inc. (OM) Q4 2023 Earnings Call Transcript
Outset Medical, Inc. (OM) Q4 2023 Earnings Call Transcript
02/21 16:05 EST - businesswire.com
Outset Medical Reports Fourth Quarter and Full Year 2023 Financial Results
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter, Year-End Results, and Recent Highlights Recorded net revenue of $30.5 million in the fourth quarter, bringing 2023 revenue to $130.4 million, a 13% increase compared to $11.
Outset Medical Reports Fourth Quarter and Full Year 2023 Financial Results
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter, Year-End Results, and Recent Highlights Recorded net revenue of $30.5 million in the fourth quarter, bringing 2023 revenue to $130.4 million, a 13% increase compared to $11.
02/05 11:05 EST - zacks.com
Outset Medical, Inc. (OM) Expected to Beat Earnings Estimates: Should You Buy?
Outset Medical, Inc. (OM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Outset Medical, Inc. (OM) Expected to Beat Earnings Estimates: Should You Buy?
Outset Medical, Inc. (OM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
02/05 08:30 EST - businesswire.com
Outset Medical to Report Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, February 21, 2024
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full-year 2023 after the close of trading on Wednesday, February 21, 2024. On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief F.
Outset Medical to Report Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, February 21, 2024
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full-year 2023 after the close of trading on Wednesday, February 21, 2024. On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief F.
01/08 08:30 EST - businesswire.com
Outset Medical Reports Unaudited Fourth Quarter and 2023 Revenue, Provides 2024 Revenue and Non-GAAP Gross Margin Guidance
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported unaudited revenue for the fourth quarter and fiscal year ended December 31, 2023, and provided 2024 financial guidance. Unaudited Fourth Quarter and Year End Results, and Recent Highlights Revenue in the fourth quarter totaled $30.5 million, bringing revenue for 2023 to $130 million,.
Outset Medical Reports Unaudited Fourth Quarter and 2023 Revenue, Provides 2024 Revenue and Non-GAAP Gross Margin Guidance
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported unaudited revenue for the fourth quarter and fiscal year ended December 31, 2023, and provided 2024 financial guidance. Unaudited Fourth Quarter and Year End Results, and Recent Highlights Revenue in the fourth quarter totaled $30.5 million, bringing revenue for 2023 to $130 million,.
01/03 08:30 EST - businesswire.com
Outset Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will present at the 42nd annual J.P. Morgan Healthcare conference on Monday, January 8, 2024, at 5:15 p.m. Pacific time. A live and archived webcast of the presentation will be available on the “Investors” section of the Outset website at https://investors.
Outset Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will present at the 42nd annual J.P. Morgan Healthcare conference on Monday, January 8, 2024, at 5:15 p.m. Pacific time. A live and archived webcast of the presentation will be available on the “Investors” section of the Outset website at https://investors.